Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.86, $0.14 better than the analyst estimate of $0.72. Revenue for the quarter came in at $386.9 million versus the consensus estimate of $384.58 million.

GUIDANCE:

Integra LifeSciences sees FY2021 EPS of $3.16-$3.20, versus the consensus of $3.04. Integra LifeSciences sees FY2021 revenue of $1.54-1.55 billion, versus the consensus of $1.54 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.